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Non-alcoholic fatty liver disease (NAFLD) is a multi-faceted disor-
der, which ranges from simple steatosis to non-alcoholic steato-
hepatitis (NASH) with/without ﬁbrosis. The effects of speciﬁc
risk factors, such as obesity and sedentary lifestyle, on predispos-
ing genetic settings eventually lead to the development of NAFLD
in children. The complex interplay between genes and environ-
ment in NAFLD pathogenesis is sustained by multiple mecha-
nisms that involve liver crosstalk with other organs and tissues,
especially gut and adipose tissue. Unfortunately, natural history
of paediatric NAFLD is lacking, and the etiopathogenesis is still
in the process of being deﬁned. Potential early predictors and
suitable non-invasive diagnostic tools can be discovered based
on the pathogenetic mechanisms and histological patterns. This
will also help design novel treatments and a comprehensive
and successful management strategy for patients.
In this review, we discuss the recent advances made in genet-
ics, etiopathogenesis, diagnosis, and therapeutic management of
NAFLD, focusing especially on the obesity-related steatotic liver
condition.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Non-alcoholic fatty liver disease (NAFLD) is a major health prob-
lem that integrates several liver conditions ranging from simple
fatty liver to non-alcoholic steatohepatitis (NASH), which is
sometimes associated with ﬁbrosis that may evolve into cirrhosis
and result into hepatocellular carcinoma [1,2]. Furthermore, as
underlined in a recent meta-analysis, NAFLD is also associated
with increased overall morbidity and mortality for cardiovascular
disease [3–5].Journal of Hepatology 20
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• Analysis of genetic background may help paediatrics
identify children susceptible to NAFLD
• Novel findings about pathogenetic mechanisms 
leading to paediatric NAFLD may improve therapeutic
performance
• Adequate diagnostic and therapeutic management
is crucial to prevent and counteract progression of
paediatric NAFLD
As the prevalence of obesity in children increases, so does the
prevalence of paediatric NAFLD [4]. This rise is worrisome
because of its close association with the development of meta-
bolic syndrome (MetS) [6–8].
Although etiopathogenesis of paediatric NAFLD remains
unknown, it is conceivable that, such as in adults, a network of
interactions among multiple factors is involved in both the devel-
opment and progression of the disease [9,10]. However, as obes-
ity-related NAFLD in children is rarely inﬂuenced by secondary
causes (e.g., severe weight loss, drug, and alcohol consumption),
it may be an excellent model to elucidate the factual origins of
primary NAFLD, including the contribution of susceptibility genes
and environment [11,12].
NAFLD is suspected mainly by the analysis of anthropometri-
cal and biochemical parameters and/or ultrasound liver bright-
ness [13]. Histological analysis of liver biopsy remains the
masterful method to differentiate simple steatosis from NASH
and to perform staging and grading of the disease in children
[14]. However, recently, advances have been made in the ﬁeld
of non-invasive evaluation of paediatric NAFLD [15].
There are no current speciﬁc therapeutic indications for the
treatment of paediatric NAFLD. However, as overweight/obesity
is often coupled with NAFLD, weight loss by diet and exercise
programs is widely accepted as the ﬁrst line of intervention in
children [16]. Poor adherence to lifestyle modiﬁcations often fails
to halt or revert the occurrence of liver damage during pathogen-
esis of paediatric NASH. Therefore, at this time, developing possi-
ble multi-targeted therapies to halt disease progression, restoring13 vol. 58 j 1218–1229
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liver cell homeostasis and repairing the damage are all funda-
mental objectives in the treatment. In fact, during the last 5 years,
a series of fairly novel pharmacological treatments have been
tested, and a wide range of newer drugs are now being developed
[17].
Here we provide an extensive overview of NAFLD in children
while discussing the most up-to-date literature in the ﬁeld. Par-
ticularly, we focus on the many interesting breakthroughs in
genetics, etiopathogenesis, diagnosis, and therapeutic manage-
ment of paediatric obesity-related liver disease.Epidemiology
The epidemics of overweight and obesity in paediatric population
has reached worldwide proportion over the last two decades
[4,13]. As a consequence, NAFLD has now become the most com-
mon cause of chronic liver disease in children and adolescents in
the USA [18], and most probably, in the rest of the industrialized
countries. The true prevalence of NAFLD, however, remains lar-
gely elusive. In fact, extrapolation of correct epidemiological data
is hampered by the large variability of available non-invasive and
invasive diagnostic tests. None of these tests are exempt from
criticisms in terms of misdiagnosis and/or invasiveness and costs.
Serum alanine aminotransferase (ALT) activity is a widely
accessible and cheap test for the screening and initial evaluation
of NAFLD. The sensitivity of this biochemical marker, however,
remains low because some adult and paediatric patients with
biopsy-proven NAFLD may present ALT values in the normal
range [19]. In an Italian study, 72 obese children presented with
ultrasonographic fatty liver (50% of cases) and/or hypertransam-
inasemia (25% of cases) [20].
To add to the difﬁculties, histology – the gold standard for the
diagnosis of NASH – may be subject to the higher probability of
staging sampling error [14]. Furthermore, epidemiological data
of a paediatric population may be inﬂuenced by a series of
crossed risk factors such as peri-pubertal age, male gender (for
NAFLD, but not for NASH), hispanic ethnicity, non-black race
and individual genetic predisposition. NAFLD and/or its progres-
sion to severe disease have, in fact, been linked to several inher-
ited variants that will be discussed extensively in the next
paragraph on genetic risk factors [21]. Familial clustering of obes-
ity, insulin resistance (IR), NAFLD or type 2 diabetes are frequent
and should raise suspicion of NAFLD in children from such fami-
lies [22,23].
Obesity and MetS are the major risk factors for paediatric
NAFLD. NAFLD prevalence is higher in overweight (gender and
age speciﬁc BMI >85th percentile) or obese (>95th percentile)
children as compared with normal weight age matched pairs.
Today, it seems clear that waist circumference (i.e., abdominal
fat or central obesity) plays a pivotal role and correlates with
NAFLD diagnosis more than BMI alone [24].
Population-based studies conducted with ALT or ultrasonog-
raphy in several countries have shown that paediatric NAFLD
prevalence remains in a range of 2.6–7.1% of children [10]. An
autoptic study in California, conducted in children deceased for
accidents, showed a prevalence of histological NAFLD ranging
from 0.7% in 2–4 year old to 17.3% in 15–19 year old subjects
[25]. In cohorts of children of various nationalities selected for
overweight or obesity, the prevalence of elevated ALT is higher
and ranges from 8 to 42%, whereas the prevalence of bright liverJournal of Hepatology 2013ranges from 1.7 to 77% [26]. In an autoptic study by Schwimmer
et al., prevalence of histological NAFLD in obese individuals was
38% [25].Genetic risk factors
In recent years, an exciting step towards the understanding of the
pathogenesis and risk factors in the development and progression
of paediatric NAFLD has been taken as a result of genetic studies.
It is indeed well known that NAFLD has a major genetic compo-
nent [23]. Because of the lower numbers of confounding factors
(e.g., the duration of disease, presence of obesity, lifestyle habits,
co-morbidities, and drugs) and the more important role of inher-
ited factors in early-onset disease, this is especially true for chil-
dren [27].
The major advance has come from the ﬁnding, ﬁrst obtained
by genome-wide association studies (GWAS) conducted in the
general adult population [28,29], that genetic variants of the pat-
atin-like phospholipase domain-containing protein-3 (PNPLA3)
and, in particular, the common rs738409 C>G single nucleotide
polymorphism (SNP) encoding the I148M variant, are not only
associated with hepatic fat content and increased serum liver
enzymes but also increase the risk of NASH and ﬁbrosis progres-
sion [30–32]. The I148M PNPLA3 variant inﬂuenced liver triglyc-
eride content without apparently affecting body mass, serum
lipid levels and systemic IR [31,33]. PNPLA3 is regulated by the
lipogenic program [34] and is highly expressed in the liver and
adipose tissue at the level of the endoplasmic reticulum and
the surface of lipid droplets, where it seems to be involved in
the metabolism of triglycerides [35]. Although the mechanism
and physiological substrates remain unclear, the common
I148M variant disrupts the activity of the enzyme, thereby alter-
ing lipid catabolism, and it might also acquire new and still
unknown functions [35]. Indeed, the association of I148M variant
with progressive liver disease and hepatocellular carcinoma is
independent of the predisposition to increased steatosis, thus
suggesting that it inﬂuences the regulation of pro-inﬂammatory
lipid mediators [27,30,32].
The association between I148M variant and both liver
enzymes and steatosis was soon conﬁrmed in obese children of
different ethnicities [36–39] and in one family study in Italian
trios [30], indicating that it exerts its effect early in life and that
the magnitude of the association between I148M PNPLA3 variant
and serum levels of liver enzymes was related to the size of
abdominal fat [40] and to the high dietary carbohydrate and
sugar consumption [41]. In addition, an interaction was reported
between dietary fatty acids composition, PNPLA3 genotype and
hepatic fat accumulation. Indeed, the omega-6/omega-3 poly-
insaturated fatty acids ratio was correlated with hepatic fat frac-
tion and ALT levels only in children homozygous for 148M
PNPLA3 variant and at risk of steatosis [42].
Furthermore, PNPLA3 genotype inﬂuenced the histological
severity of NASH alterations and ﬁbrosis in obese paediatric
patients who underwent biopsy because of persistently altered
liver enzymes. Interestingly, the association with ﬁbrosis was
stronger in children than in adults, in that each 148M allele
increased the risk of ﬁbrosis by almost twofold [27].
A more recent GWAS, conducted in a larger population, was
able to identify a wider set of genetic variants inﬂuencing steato-
sis besides I148M of PNPLA3 [43]. Of these variants, rs2854116vol. 58 j 1218–1229 1219
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SNP of glucokinase regulator (GCKR), involved in the regulation of
uptake of monosaccharides and lipogenesis, was conﬁrmed to
predispose to fatty liver and dyslipidemia in obese children and
adolescents independent of PNPLA3 [44], although the effect on
histological progression of liver disease remains unknown, espe-
cially in view of the ameliorating effect on IR.
Besides, additional SNPs of genes implicated in NASH patho-
genesis have been shown to inﬂuence liver damage and ﬁbrosis
progression in candidate gene case-control studies including pae-
diatric patients. These include genetic variants regulating insulin
receptor activity, namely the ectoenzyme nucleotide pyrophos-
phate phosphodiesterase 1 (ENPP1) Lys121Gln and the insulin
receptor substrate-1 (IRS-1) Gly972Arg functional SNPs [45], thus
underscoring the causal role of IR in the progression of liver dam-
age in NAFLD. The manganese superoxide dismutase (SOD2) C47T
rs4880 SNP, regulating SOD2 mitochondrial import and antioxi-
dant activity [46], and the Kruppel-like factor 6 (KLF6) IVS1-
27G>A SNP, regulating alternative splicing isoforms of the tran-
scription factor KLF6, involved in the regulation of metabolism
in hepatocytes and ﬁbrogenesis in hepatic stellate cells, seem to
be involved as well [47]. In contrast, variants in the hemochroma-
tosis gene (HFE), regulating iron metabolism and in the apolipo-
protein-C3 (APOC3), regulating very low density lipoprotein
metabolism, were not conﬁrmed to inﬂuence susceptibility stea-
tosis and NASH [48,49].
Finally, there is a growing awareness that the expression of
some genetic variants may be age-dependent, i.e., the phenotype
may be more (or less) marked or involve different traits during
the developmental age. For example, a common variant
(rs13412852) inﬂuencing the expression of lipin-1 (LPIN1),
another lipid phosphatase involved in adipogenesis and regulat-
ing the ﬂux of free fatty acids between the adipose tissue and
the liver, whose expression is deregulated during steatosis [50],
was associated with lipid levels, NASH severity, and hepatic ﬁbro-
sis in children with NAFLD, whereas it inﬂuenced body mass in
adults of the same ethnicity [51]. In Table 1, we have summarized
genetic polymorphisms inﬂuencing the susceptibility to paediat-
ric NASH.Table 1. Genetic variants inﬂuencing the susceptibility to NAFLD and NASH during t
Gene Function SNP
PNPLA3, patatin-like 
phospholipase domain containing 3
Lipid remodelling, 
lipogenesis
rs738409 C
GCKR, glucokinase regulatory protein Glucose uptake, 
lipogenesis
rs780094 C
SOD2, superoxide dismutase 2, 
mitochondrial
Anti-oxidant response rs4880 C>
ENPP1, ectonucleotide 
pyrophosphatase/phosphodiesterase 1
Insulin signalling rs1044498
IRS1, insulin receptor substrate 1 Insulin signalling rs1801278
KLF6, Kruppel-like factor 6 Fibrogenesis, glucose 
metabolism and lipogenesis
rs3750861
LPIN1, lipin-1 Lipogenesis, adipogenesis rs1341285
SNP, single nucleotide polymorphism; MAF, minor allele frequency, in European health
The number of arrows is related to the strength of both the genetic association and the
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development
It is widely accepted that genetic susceptibility, epigenetic mech-
anisms, physical inactivity, and excess caloric intake by diet inﬂu-
ence visceral fat accumulation inducing an obese and
metabolically dysfunctional phenotype [52]. This pattern, charac-
terized by abdominal obesity, IR, impaired glucose tolerance,
dyslipidemia, and hypertension, deﬁnes a subject with MetS.
NAFLD is generally associated with at least one of these MetS fea-
tures in adults, and emerging evidence conﬁrms the existence of
a similar relationship in children as well [52,53,12]. An Italian
study demonstrated that 65.8% of 120 children (age range: 3–
18 years) with biopsy-proven NAFLD presented with MetS, which
was also associated with ﬁbrosis grade [54]. Approximately 26%
of 254 children adolescents (age range: 6–17 years) enrolled in
the Non-alcoholic Steatohepatitis Clinical Research Network
(NASH CRN) met speciﬁed criteria for MetS diagnosis [55]. These
data, as well as other contributions [6–8], highlight the potential
role of NAFLD as co-factor of other obesity-related co-morbidities
in a paediatric population.
In the last decade, the concept that increased consumption of
obesogenic food may have a role in the pathogenesis of NAFLD
has spread. In fact, apart from the impact of the genetic back-
ground, hypercaloric diets (particularly those enriched in fat
and fructose/sucrose) may act by favouring the occurrence of sys-
temic IR and, in turn, a dangerous hepatic free fatty acid (FFA)
accumulation or causing visceral fat deposition and consequent
hepatic IR, accountable for development of fatty liver [56,57].
According to the ‘multiple hits’ hypothesis, IR and FFA accumula-
tion may predispose the fatty liver to secondary hits, including
the imbalance of production/release of hormones derived from
adipose tissue (adipocytokines), oxidative stress, activation of
speciﬁc nuclear receptors and ﬁbrogenesis [58,59]. In order to
counteract the IR, the number of pancreatic b cells increases,
resulting in a compensatory hypersecretion of insulin. This over-
ﬂow of circulating insulin accelerates liver fat storage leading to
NAFLD.he developmental age.
Protein 
variant
Activity MAF Effect on 
steatosis
Effect on 
NASH
>G Ile148Met Increased
lipogenesis ?
0.19 ↑↑ ↑↑
>T Pro446Leu Loss of regulatory 
function
0.45 ↑ ?
T Ala16Val Loss of mitochondrial 
import
0.49 none ↑
 A>C Lys121Gln Loss of inhibitory 
function
0.29 none ↑
 G>C Gly972Arg Loss of function 0.05 none ↑
 G>A IVS1-27G>A Altered splicing 0.06 ? ↑
2 C>T Non coding 
SNP
Unknown 0.35 ↑ ↑
fibrosing
y subjects.
available evidence.
vol. 58 j 1218–1229
PAMPs
DAMPs
Proteins
Intestinal epithelium
Carbohydrates
Lipids
Bacteria
Diet
Macrophages
Adipocytokines
Adipose tissue
FFAsLiver
Hepatocytes
HSCs
Kupffer cells
Insulin
Pancreas
Fig. 1. Schematic representation of the crosstalk among different organs during NAFLD development.
JOURNAL OF HEPATOLOGYIn this already complex network of organ crosstalk, a crucial
role of the gut has been recently considered. In fact, it has been
suggested that the diet- and/or gut-microbiota-dependent
increase of gut-derived products, and the consequent release of
pathogen- or damage-associated molecular patterns (PAMPs or
DAMPs), may cross a reduced gut permeability barrier, activate
molecular mechanisms of innate immune response, and act as
possible inductors of necroinﬂammatory lesions and severe ﬁbro-
sis in the progression of simple fatty liver to NASH [60,61]. Inter-
estingly, the lipopolysaccharide (LPS), one of most studied PAMPs,
in association with plasminogen activator inhibitor-1 (PAI-1), has
a mild to moderate correlation with steatosis and NAS [62].
All these ﬁndings suggest that, although the pathogenesis of
NAFLD remains the subject of intense debate, fatty liver develop-
ment and eventually its progression to NASH are the result of a
crosstalk among different organs, including adipose tissue, pan-
creas, gut, and liver (Fig. 1).Cellular andmolecular signatures in the pathogenesis of NASH
NASH represents a histological progressive condition and a major
cause of what was previously considered as cryptogenic cirrhosis
[63–65]. Progression of simple fatty liver towards a condition ofJournal of Hepatology 2013inﬂammation and ﬁbrosis is characterized by the contribution
of multiple mechanisms that differently regulate the physiologi-
cal liver response, although why this occurs in some patients
only, remains unknown [66–69].
The cellular basis of liver ﬁbrosis in NASH
Fibrogenesis mainly occurs in extracellular matrix (ECM) remod-
elling, which is regulated by three different cell types: (1) endog-
enous (resident) ﬁbroblast or myoﬁbroblast-like cells, mainly
represented by hepatic stellate cells (HSCs) and also by portal
ﬁbroblasts; (2) ﬁbrocytes recruited from the bone marrow to
the liver during the development of chronic hepatic injury; (3)
the potential engraftment and differentiation of bone marrow-
derived mesenchymal stem cells into myoﬁbroblast-like cells
[70]. In addition to the previous points, another source of colla-
gen-producing cells might be derived from the process of ductu-
lar reaction and the so-called epithelial-mesenchymal transition
(EMT), via which epithelial cells can transdifferentiate into mes-
enchymal cells to acquire the ability of producing collagen
[70,71]. Although HSCs are considered the main ECM-producing
cells during the development of NASH, detailed studies to dissect
the real contribution of each ﬁbrogenic phenotype are lacking.
Considering this, the possibility that the elements of the ductularvol. 58 j 1218–1229 1221
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reaction might undergo EMT has been recently questioned [71].
However, the elements of the ductular reaction represent the
hepatic progenitor cell (HPC) compartment of the liver, and it
has been recently shown that the HPC compartment, especially
in children with NASH, was expanded and independently associ-
ated with the degree of ﬁbrosis [72].
Role of adipocytokines
Key players in the progression from simple steatosis to NASH are
the so-called adipocytokines including adiponectin, leptin, resi-
stin, tumour necrosis factor (TNF)a and interleukins (ILs)
secreted by adipocytes or the inﬂammatory cells that inﬁltrate
the adipose tissue in insulin-resistant conditions.
Leptin downregulates insulin signalling in the liver and
reduces ﬁbrosis in experimental models of ﬁbrosis and NASH.
Leptin may activate HSC through the NADPH oxydase system
[73–77]. In contrast, it has been clearly demonstrated in a previ-
ous study that adiponectin can counteract the IR effect of leptin,
exert anti-inﬂammatory actions and inhibit HSC proliferation,
thus interfering with ﬁbrogenesis [78].
Cytokines, particularly TNFa, IL-6, and IL-1, are involved in the
recruitment and activation of Kupffer cells and transformation of
HSC into myoﬁbroblasts. Levels of TNFa and IL-6 are often ele-
vated in the liver and blood of patients with NASH, and inhibition
of these cytokines has been shown to improve NAFLD in rodents
[79,80].
Role of oxidative stress and lipotoxicity
In a normal liver, antioxidant systems such as superoxide dismu-
tase and catalase efﬁciently remove reactive oxygen species
(ROS) produced during cellular metabolism and maintain normal
cell homeostasis [81]. Oxidative stress is increased in patients
with NASH [82]. Excess of non-esteriﬁed fatty acids (NEFA) sup-
ply to the liver increases mitochondrial and peroxisomal oxida-
tion, promote microsomal induction of CYP4A1 and CYP2E1,
and cause elevated production of ROS [83]. Among ROS produc-
ing systems, the NADPH oxidase (NADPH) complex plays a major
role in hepatic ﬁbrogenesis and collagen production. This system
also plays a crucial role in ROS production in both Kupffer cells
and HSCs during hepatic ﬁbrogenesis [84,85]. Kupffer cells in
the liver mainly produce ROS through the phagocytic form of
NADPH, which plays an important role in host defence and
inﬂammation [86,87], HSCs express the non-phagocytic form that
plays an important role in regulating cell signalling and can be
stimulated by ﬁbrogenic molecules such as leptin [88,89].
The pathogenesis of NASH also takes into consideration the
concept of lipotoxicity. The most recent hypothesis for this is that
excessive intra-hepatic lipid accumulation triggers a local necro-
inﬂammatory response, subsequently producing free radicals that
can result in damage to the cell membrane and DNA [90–92].
Thus, the cytotoxic products of lipid peroxidation induce apopto-
sis signals in hepatocytes and play a role in liver ﬁbrogenesis by
modulating HSCs behaviour in a paracrine manner [93,94].
Role of nuclear receptors in the pathogenesis of NASH
Nuclear receptors (NRs) are ligand-activated transcription factors
that regulate the expression of speciﬁc genes controlling a broad
range of cellular and metabolic functions [95,96].1222 Journal of Hepatology 2013Among NRs, the peroxisome proliferator-activated receptors
(PPARs) have been studied the most because of the presence of
pharmacological ligands [96]. PPARs are involved in the activa-
tion of HSCs [97,98]. In addition to PPARs, other NRs, such as
the farnesoid X receptor (FXR), xenobiotic sensors (CAR and
PXR), liver X receptor (LXR), and hepatocyte nuclear factor 4
(HNF4), have also been implicated in the pathogenesis of NAFLD,
but their role in the development of NASH remains to be estab-
lished [99].Diagnostic tools
Considering the lack of speciﬁc symptoms and/or signs of NAFLD,
early detection of NAFLD in children may be effective to identify
subjects with potential silent progressive fatty liver [5]. In addi-
tion, the screening for NAFLD should be recommended to over-
weight and obese children [100–102].
In the ﬁrst assessment of children with suspicion of fatty liver,
clinicians should take an accurate clinical history with particular
attention to information regarding the nutritional habits and pos-
sible drug consumption.
Routine laboratory tests
ALT elevation is common in boys and girls with fatty liver
[103,104]. In epidemiological studies, elevated ALT seems to be
associated with MetS in children and adolescents [105,106]. In
a tertiary centre setting, NAFLD associated hypertransaminas-
emia was responsible for about 20% of all cases [107].
Recently, the American Academy of Paediatrics recommended
screening with liver function tests (ALT, AST) in children aged
10 years in case of BMI P95th percentile or between 85th and
94th percentile with risk factors. The biochemistry test panel
should also include lipid proﬁling and fasting glucose determina-
tion [14,108].
Some considerations concerning the signiﬁcance of liver
enzymes are mandatory. Serum aminotransferases that are
inﬂuenced by dietary habits and hyperalimentation, may reﬂect,
in some case the presence of steatosis [109]. However, as the
serum levels of aminotransferases may be reduced even in the
presence of NASH and ﬁbrosis, liver function test cannot repre-
sent the severity of NAFLD [110]. Another major issue with ami-
notransferases lies in the variability among centres and the need
of ‘biology-based thresholds’ to increase sensitivity, as recently
underlined in the SAFETY study [111]. In this study, the thresh-
olds of 25.8 U/L in boys and 22.1 U/L in girls have been pro-
posed as a reliable index for suspicion of a chronic liver
disease. Obese children who become hepatopatic should deﬁ-
nitely be tested for causes of liver diseases other than NAFLD,
particularly for those conditions that are rapidly progressive if
not adequately treated (e.g., autoimmune hepatitis and Wilson
disease). The so-called NASH trash bin should also be carefully
taken into consideration, especially in early-onset NAFLD among
young children [14].
US and radiology
Liver ultrasound (US) can detect fatty liver when steatosis
involves >30% of hepatocytes [112]. US has several advantages
for use as a screening tool: relative low cost, large diffusion invol. 58 j 1218–1229
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medical community and feasibility. Recently, a large prospective
paediatric cohort showed a good correlation between ultrasono-
graphic steatosis score and the severity of steatosis on liver
biopsy [113]. Moreover, US has been used to assess the outcome
of efﬁcacy in paediatric trials with good compliance between the
outcomes of children and parents [114].
Computed tomography (CT) scan is not recommendable in
paediatric setting because of the unjustiﬁed radiation exposure
involved in the process. In contrast, magnetic resonance imaging
(MRI) has been demonstrated to have good sensitivity in quanti-
ﬁcation of fat in the liver [115,116].Progression indexes
The main challenge for paediatric hepatologists is the identiﬁca-
tion of children with higher probability of progression to a more
severe form of liver disease.
Ultrasound-guided or assisted needle liver biopsy remains the
gold standard method for deﬁning diagnosis, severity, and rate of
progression of NASH to its clinical sequelae. Because it is an inva-
sive tool for monitoring therapeutic responses and disease evolu-
tion, research on clinical parameters or serum markers that can
identify subjects with steatohepatitis and who are prone to fur-
ther progression has been undertaken.
Several studies have aimed at identifying clinical parameters
that can predict the progression of a liver disease. The presence
of necro-inﬂammation at liver biopsy is associated with a possi-
ble rapid progression of ﬁbrosis [54]. Results of clinical studies
have indicated BMI, lipid proﬁle, IR, and fasting glucose as predic-
tors of NAFLD in children [14]. Moreover, waist circumference
alone seems to be correlated with liver ﬁbrosis in the paediatric
setting [117]. In conclusion, simple clinical parameters such as
age (expression of length of disease), IR surrogate clinical marker
acanthosis nigricans, anthropometrical data (BMI, waist), lipid,
and glucose proﬁle can allow a clinician to recognise children
with potential severe NAFLD. The Paediatric NAFLD Fibrosis Index
(PNFI) algorithm was developed on the basis of waist circumfer-
ence, triglycerides, and age [118].
The need of a simple and reliable tool for the assessment and
monitoring of liver ﬁbrosis has boosted the research of ‘non-inva-
sive’ markers. Unfortunately, limited sample size, lack of ade-
quate information regarding the control groups and quality of
liver specimen, and lack of validation in large and independent
cohorts have together reduced the application of this tool in clin-
ical practice [119].
Several molecules are involved in ECM remodelling during
ﬁbrogenesis: the matrix metalloproteinases (MMPs) that partici-
pate in ECM degradation; their speciﬁc tissue inhibitors, the tis-
sue inhibitor of metalloproteinases-1 (TIMPs), and various
cytokines that stimulate HSC conversion into myoﬁbroblast-like
cells that synthesize hyaluronic acid (HA), which has been found
as a reliable marker of ﬁbrosis deposition in children [120].
However, a recent paper suggests that the more reliable
serum marker of steatohepatitis is cytokeratin-18 (CK18) frag-
ment levels, which are increased in the bloodstream according
to the presence and severity of NASH [121].
Recently, the enhanced liver ﬁbrosis (ELF) panel of serum
markers (tissue inhibitor of matrix metalloproteinase 1, HA, and
aminoterminal peptide of pro-collagen III) was tested in a
paediatric cohort to show the capability of prediction of ﬁbrosis
[122].Journal of Hepatology 2013In a recent study, the combination of ELF and PNFI showed
good accuracy in predicting ﬁbrosis in children with histologi-
cally conﬁrmed NAFLD [123].
Transient elastography appears to be a more promising tool
for non-invasive assessment of ﬁbrosis, and its role in paediatric
NAFLD has been recently reviewed elsewhere, unfortunately the
lack of capability to discriminate between intermediate degrees
of ﬁbrosis represents the major limitation to avoid liver biopsy
for the diagnosis of ﬁbrosis in NASH [124].Treatments
The aim of this section is to evaluate established and other pos-
sible novel NAFLD treatment options in the paediatric age group
by providing recent evidence from the literature. Fig. 2 illustrates
a synoptic summary of most pathogenetic mechanism-based
treatments.
Diet and lifestyle changes
The goal of lifestyle interventions is a gradual and controlled
weight loss achieved by diet and physical exercise. Unfortunately,
this aim is difﬁcult to achieve and the results are disappointing,
with an extremely low percentage of individuals who are able
to steadily lose weight and exercise regularly [16]. Weight loss
in NAFLD patients on diet improves hepatic insulin sensitivity
by reducing hepatic FFA supply, improves extra-hepatic insulin
sensitivity through better glucose utilization and reduces ROS
generation and adipose tissue inﬂammation. Exercise and out-
door activities are also promoted because they may improve sub-
strate utilization in muscles and contribute to obtaining better
insulin sensitivity, irrespective of weight loss [125].
Weight loss (approximately 5–10% of the basal weight) should
be gradual, since extreme slimming diets may lead to the onset of
severe metabolic disorders and promote liver damage. Indeed,
some studies in children conﬁrmed an improvement in serum
aminotransferase levels and several metabolic parameters
including lipids, fasting glucose, insulin, and insulin sensitivity
indices [126–128]. Interestingly, Nobili et al. showed that a
repeated biopsy at 24 months displayed signiﬁcant improvement
of liver histology with reduction of the grade of steatosis, hepatic
lobular inﬂammation, hepatocyte ballooning, and NAFLD activity
score [129].
Currently, there are no precise evidence-based guidelines
establishing the optimal dietary interventions. Reduction in
sugar/sucrose and in soft drinks rich in fructose, most probably
not only acts through a reduction in IR and lipogenesis but also
counteracts the recently evidenced hepatic pro-inﬂammatory/
ﬁbrogenetic role of fructose [130].
Diet in childhood must be balanced to allow a healthy and
harmonic growth, including wellness of bone structures. Reduced
dietary intake of saturated/trans fat, increased intake of polyun-
saturated fat (omega-3) [131], and increased ﬁbres intake [132]
have been proposed as other valuable measures. Diets rich in
ﬁbres, however, should be approached with caution because poor
information is available on the possible side effects of ﬁbres when
used in large amounts in children. Unfortunately, lifestyle inter-
vention has only a very moderate effect on weight loss, with
<10% success rate 2 years after the onset of intervention. A reduc-
tion of >0.5 SDS-BMI (indicating stable weight over 1 year invol. 58 j 1218–1229 1223
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Fig. 2. Schematic representation of the pathogenetic mechanism-based NAFLD armamentary. Established and potential therapies targeting a given pathway are
depicted in the upper and lower part of the cartoon, respectively.
Reviewgrowing children) is associated with an improvement of cardio-
vascular risk factors, while improvements in quality of life seem
independent of the degree of weight loss. Younger children and
less overweight children particularly proﬁt from lifestyle inter-
ventions as compared with extremely obese adolescents [133].
Durable weight loss can be achieved with bariatric surgery,
especially in adolescents; however, the guidelines for eligibility
remain to be standardized. In adults, this therapeutic option
improves liver damage [134]. However, there are very scarce data
on the NAFLD adolescent population, and a comparison with
untreated natural history data is required [135,136].Pharmacological interventions for NAFLD
The pharmacological approach, in NAFLD children poorly adher-
ent to or being unresponsive/partially responsive to lifestyle
changes, is aimed at acting upon speciﬁc targets involved in eti-
opathogenesis (Fig. 2). The following drugs have been more
extensively used and include antioxidants, insulin sensitizers,
and cytoprotective agents.
Antioxidants, by reducing oxidative stress, protect susceptible
components of biological membranes from lipid peroxidation,
and may therefore be able to prevent the progression of simple
steatosis to NASH. The most studied antioxidant in children with
NAFLD is alpha-tocopherol (vitamin E). The ﬁrst open-label pae-
diatric trial with vitamin E (400–1.200 IU/day), involving 11 chil-
dren with NAFLD, showed a decrease of serum aminotransferase
levels not associated with a reduction in BMI values and bright
liver at ultrasonography [137]. Other studies comparing the effect
of vitamin E vs. that of single weight loss, did not ﬁnd a higher
efﬁcacy of antioxidant treatment as compared with exclusive life-
style changes [138,139]. Nobili et al. demonstrated that adding1224 Journal of Hepatology 2013ascorbic acid to vitamin E was still not better than lifestyle inter-
vention alone [129].
Lavine et al. [140], in a more recent large, multicenter, ran-
domised double-blind placebo-controlled trial (TONIC study),
evaluated the effect of a 96-week antioxidant therapy with vita-
min E (400 IU twice daily), insulin sensitizer metformin (500 mg
twice daily) or placebo in children with NAFLD. A total of 173
patients (aged 8–17 years) with biopsy-conﬁrmed NAFLD and
persistently elevated levels of ALT, without diabetes or cirrhosis,
were randomly assigned to 1 of 3 groups. At 96 weeks, vitamin E
treatment was not better or worse than the placebo treatment in
reducing ALT and was only able to improve histological hepato-
cellular ballooning in NAFLD and NASH. Other antioxidants, par-
ticularly betaine and silymarin, are possible promising
therapeutic tools for NAFLD [141], but more data are required
for the paediatric age.
For its pathogenetic role, IR is a rational therapeutic target.
Metformin is the only insulin-sensitizing agent evaluated in chil-
dren. A single-arm, open-label, pilot study on metformin (500 mg
twice daily for 24 weeks), conducted in 10 non-diabetic children
with biopsy-proven NASH and elevated ALT levels, showed
reduction of hepatic steatosis, as evaluated with Magnetic Reso-
nance Spectroscopy (MRS), and low serum ALT levels [142]. On
the other hand, a subsequent study in the paediatric age by com-
paring metformin with lifestyle interventions did not conﬁrm the
advantages of using this drug [143], whereas another study [144]
demonstrated a noteworthy improvement in fatty liver preva-
lence and severity in a selected cohort of 50 obese and insulin-
resistant adolescents and in fasting insulin in metformin com-
pared with placebo patients. Finally, the most recent TONIC study
showed that metformin, like vitamin E, was no better or worse
than placebo in reducing ALT and was able to improve histologi-
cal hepatocellular ballooning only in NAFLD [140]. As comparedvol. 58 j 1218–1229
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to placebo, both vitamin E and metformin signiﬁcantly improved
ballooning, but neither of them led to a signiﬁcant improvement
in other histological features.
There are still insufﬁcient data about the possibility of use of
the glitazones, drugs believed to have a role in the treatment of
adult NAFLD [145], in NAFLD-affected children.
UDCA (ursodeoxycholic acid) is a hydrophilic bile acid that
normally constitutes 3% of the human biliary pool [146]. UDCA
might theoretically interfere with the progression of NAFLD/
NASH through the following different pathways: (1) protecting
hepatocytes from mitochondrial membrane injury mediated by
bile salts, (2) playing an immunomodulatory function, and (3)
activating anti-apoptotic signalling pathways. A pilot randomised
controlled trial involving 31 NAFLD-affected children [147]
showed that conventional dosage of UDCA is not effective on
ALT levels and ultrasonographic bright liver improvement.
Data from NAFLD animal model studies suggests that gut mic-
robiota manipulation with probiotics reduces liver inﬂammation
and improves gut epithelial barrier function, thus representing a
novel advantageous therapeutic approach in NAFLD patients
[148–150].
In human NAFLD, Loguercio et al. evaluated the effects of
chronic therapy with a probiotic (VSL#3) in patients affected by
several types of chronic hepatopaties, including NAFLD. Results
of the study suggested that probiotics warrant consideration as
an additional beneﬁcial therapy in some types of chronic liver
disease, such as NAFLD [151]. In obese children with persisting
hypertransaminasemia and ultrasonographic bright liver, a dou-
ble-blind, placebo-controlled, short-term pilot study showed that
after 8 weeks of treatment, patients receiving probiotics therapy
vs. placebo attained a signiﬁcant improvement of serum ALT and
antipeptidoglycan-polysaccharide antibodies levels, a surrogate
test for gut microbiota dysbiosis evaluation, independently of
weight, waist, and abdominal fat changes [152]. Overall, these
results, in association with their excellent tolerability, suggest
the use of probiotics as a promising therapeutic tool in paediatric
NAFLD.
Polyunsaturated fatty acids (PUFAs) are fatty acids that con-
tain more than one double bond in their backbone. This class
includes many important compounds, such as essential fattyTable 2. Novel potential NAFLD treatment targets still partially explored in
adults and/or children.
Drug class Target/mechanism 
of action
References
Probiotics Gut-liver axis Vajro et al., 2011
Omega-3 DHA 
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Dyslipidemia/insulin 
resistance
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Journal of Hepatology 2013acids, like omega-3 and omega-6 acids. The term ‘essential fatty
acid’ refers to fatty acids that the body needs, but cannot produce.
Essential fatty acids serve multiple functions; in each of them, the
balance between dietary x-3 and x-6 strongly affects function.
PUFAs can be found in several natural foods. PUFAs have a variety
of health beneﬁts when they are consumed in moderation and as
a part of a diet high in ﬁbre [153].
Recent pharmacological studies in NAFLD animal models and
in human adults, focusing on the effect of oral treatment with
omega-3 fatty acids, showed both anti-inﬂammatory and insu-
lin-sensitizing properties, suggesting a role of this lipid in the
treatment of NAFLD [153]. In NAFLD children, a recent double-
blind RCT [131] investigated the effect of x3-docosahexaenoic
acid (DHA) supplementation on the decrease of liver fat content,
evaluated by ultrasonographic bright liver after 6 months of
treatment. DHA taken orally for 6 months improves bright liver
and insulin sensitivity, without signiﬁcant differences between
doses of 250 and 500 mg/day. Because x3 fatty acids are well tol-
erated by the paediatric population, therapy with DHA warrants
consideration in the management of paediatric patient with
NAFLD. Randomised placebo-controlled trials are therefore
needed.
Promising novel therapeutic approaches
Here, we discuss other interesting approaches that have hitherto
been explored only in NAFLD animal models or in adults (Table 2),
and which will perhaps become the object of study in the paedi-
atric population in future.
Incretin mimetics and DPP-4 inhibitors increase insulin secre-
tion through different pharmacological mechanisms. Exenatide
and liraglutide are glucagon-like peptide (GLP)-1 receptor ago-
nists, resistant to DPP-4 degradation [141]. Sitagliptin is a selec-
tive DPP-4 inhibitor that enhances GLP-1 and glucose-dependent
insulinotropic peptide (GIP) serum levels. An extra-pancreatic
protective role of sitagliptin in diet-induced adipose tissue
inﬂammation and hepatic steatosis has also been shown in dia-
betic mice [154].
FXRs are NRs seemingly involved in the NAFLD pathogenesis
[155]. Bile acids act as endogenous ligands for these receptors,
mediating a variety of functions as follows: (1) control of lipids
homeostasis with a beneﬁcial effect on dyslipidemia; (2) glucose
metabolism regulation (mechanism is still unknown, but FXR
ablation in mice led to glucose intolerance); (3) reduction of
hepatic inﬂammation and ﬁbrogenesis through different mecha-
nisms. Therefore, FXR agonist might have a role in the pharmaco-
logical therapy of NAFLD/NASH. However, future studies are
expected, especially in adults, due to their narrow therapeutic
range or poor safety proﬁle [156].
Cysteamine bitartrate is a potent antioxidant that readily tra-
verses cellular membranes and can increase the levels of all
adiponectin multimers [157]. In a recent pilot study, enteric-
coated cysteamine was shown to be of potential beneﬁt in
NAFLD-affected children [158].
Some studies in NASH-affected adults showed a role of pen-
toxifylline, a phosphodiesterase inhibitor that exerts its immuno-
modulatory functions antagonizing the pathway of TNF-a, in
reduction of serum ALT levels and in histological features such
as steatosis, lobular inﬂammation, and ﬁbrosis stage [159]. More
research is needed, especially in paediatric patients, where thevol. 58 j 1218–1229 1225
Review
treatment seems interesting especially in view of the good toler-
ability reported in NASH–affected adults [160].
TLRs are a group of receptors that recognise PAMPs and
DAMPs. TLR2, TLR4, and TLR9 seem to be involved in NAFLD path-
ogenesis [61,161]. TLRs stimulation results in activation of the
transcriptional factor NF-jB, crucial for the inﬂammatory
response and implicated in the progression of NAFLD to NASH.
Upon stimulation, hepatic immune cells produce various media-
tors (cytokines and chemokines) that alter lipid metabolism,
insulin signalling, cell survival, and ﬁbrogenesis. For their ability
to antagonize TLRs pathway in Kupffer cells and natural killer T
cells, antagonists of TLRs may represent a novel tool in NAFLD
therapy [10,161].Conclusions
NAFLD in children is a new global challenge for liver disease
researchers and an important burden for healthy systems.
Paediatric NAFLD has a cause-and-effect complex relationship
with several metabolic abnormalities that increases the risk of
MetS and cardiovascular diseases. Therefore, fundamental
research studies are urgently required to investigate the mecha-
nisms by which these inherited or acquired traits inﬂuence
NAFLD. These advances may have a high clinical translationality
in diagnosis as well as in therapy. In fact, although diagnosis of
NAFLD in children is currently based upon invasive and non-inva-
sive approaches, concomitant efforts should be directed in the
identiﬁcation of novel tools for large-scale screening of paediatric
populations at risk. Finally, as no exact guideline exists on NAFLD
optimal therapy, in case of poor compliance to diet and lifestyle
changes and/or in case of partial or no response, integrated
multi-disciplinary programs for prevention and multi-targeted
treatment in children are required to combat the escalation and
progression of this disease.Conﬂict of interest
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